Cannara Biotech Inc. Stock Canadian Securities Exchange
Equities
LOVE
CA13765U1012
Healthcare Facilities & Services
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- CAD | -.--% | -.--% | +87.50% |
Jan. 29 | Cannara Biotech Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023 | CI |
2023 | Cannara Biotech Inc. Reports Earnings Results for the Full Year Ended August 31, 2023 | CI |
Sales 2022 | 35.84M 26.24M | Sales 2023 | 57.26M 41.92M | Capitalization | 90.41M 66.18M |
---|---|---|---|---|---|
Net income 2022 | 2M 1.46M | Net income 2023 | 6M 4.39M | EV / Sales 2022 | 4.32 x |
Net Debt 2022 | 36.28M 26.56M | Net Debt 2023 | 41.51M 30.39M | EV / Sales 2023 | 2.3 x |
P/E ratio 2022 |
135
x | P/E ratio 2023 |
12.9
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 50.58% |
Managers | Title | Age | Since |
---|---|---|---|
Zohar Krivorot
CEO | Chief Executive Officer | 48 | 18-12-30 |
Nicholas Sosiak
DFI | Director of Finance/CFO | - | 19-03-31 |
Avi Krivorot
CTO | Chief Tech/Sci/R&D Officer | - | 21-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jacob M. Kay
BRD | Director/Board Member | 83 | 19-05-24 |
Donald Olds
BRD | Director/Board Member | 64 | 20-11-09 |
Zohar Krivorot
CEO | Chief Executive Officer | 48 | 18-12-30 |
1st Jan change | Capi. | |
---|---|---|
+27.84% | 272M | |
+28.81% | 269M | |
+48.84% | 200M | |
+38.04% | 134M | |
-41.00% | 124M | |
-28.57% | 121M | |
+115.91% | 120M | |
+150.00% | 75.33M | |
-3.85% | 66.62M |
- Stock Market
- Equities
- LOVE Stock
- LOVE Stock